Business Description
Galmed Pharmaceuticals Ltd
NAICS : 325412
SIC : 2834
ISIN : IL0011313900
Description
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 263.68 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 49.8 | |||||
3-Year EPS without NRI Growth Rate | 49.9 | |||||
3-Year FCF Growth Rate | 50.8 | |||||
3-Year Book Growth Rate | -55.4 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 38.69 | |||||
9-Day RSI | 34.52 | |||||
14-Day RSI | 35.26 | |||||
6-1 Month Momentum % | -12.37 | |||||
12-1 Month Momentum % | -87.77 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.34 | |||||
Quick Ratio | 6.34 | |||||
Cash Ratio | 6.13 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -52.5 | |||||
Shareholder Yield % | 5.32 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -49.11 | |||||
ROA % | -41.36 | |||||
ROIC % | -212.31 | |||||
ROC (Joel Greenblatt) % | -3910.9 | |||||
ROCE % | -53.23 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.15 | |||||
Price-to-Tangible-Book | 0.15 | |||||
EV-to-EBIT | 1.54 | |||||
EV-to-EBITDA | 1.55 | |||||
EV-to-FCF | 1.69 | |||||
Price-to-Net-Current-Asset-Value | 0.2 | |||||
Price-to-Net-Cash | 0.2 | |||||
Earnings Yield (Greenblatt) % | 64.94 | |||||
FCF Yield % | -317.73 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Galmed Pharmaceuticals Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -2.213 | ||
Beta | 1.4 | ||
Volatility % | 84.57 | ||
14-Day RSI | 35.26 | ||
14-Day ATR (€) | 0.00837 | ||
20-Day SMA (€) | 0.2846 | ||
12-1 Month Momentum % | -87.77 | ||
52-Week Range (€) | 0.242 - 2.4 | ||
Shares Outstanding (Mil) | 6.36 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Galmed Pharmaceuticals Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Galmed Pharmaceuticals Ltd Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Galmed Pharmaceuticals Ltd Frequently Asked Questions
What is Galmed Pharmaceuticals Ltd(FRA:GPH)'s stock price today?
The current price of FRA:GPH is €0.26. The 52 week high of FRA:GPH is €2.40 and 52 week low is €0.24.
When is next earnings date of Galmed Pharmaceuticals Ltd(FRA:GPH)?
The next earnings date of Galmed Pharmaceuticals Ltd(FRA:GPH) is 2024-07-08 Est..
Does Galmed Pharmaceuticals Ltd(FRA:GPH) pay dividends? If so, how much?
Galmed Pharmaceuticals Ltd(FRA:GPH) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |